However, significant limitations exist in the current evidence: Most human data comes from small studies, with limited randomised controlled trials specifically designed to assess alcohol consumption The mechanisms by which GLP-1 medications might reduce alcohol intake are not fully understood Individual responses vary considerably, and not all patients experience changes in drinking behaviour Long-term effects and safety of using these medications specifically for alcohol reduction remain unknown The MHRA has not approved GLP-1 receptor agonists for alcohol use disorder, and these medications should not be considered a treatment for problematic drinking
GLP-1 medications are generally intended for long-term use and stopping them is not recommended without first speaking with a doctor
have or have had an eating disorder called anorexia or bulimia
[3] If IPF is suspected, diagnosis can be challenging but a multidisciplinary approach involving a pulmonologist, radiologist and pathologist expert in interstitial lung disease has been shown to improve the accuracy of IPF diagnosis
However, further research is needed to understand its efficacy and safety in humans fully
doi: 10.1684/ejd.2012.1884
